<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529122</url>
  </required_header>
  <id_info>
    <org_study_id>MX39897</org_study_id>
    <nct_id>NCT04529122</nct_id>
  </id_info>
  <brief_title>A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test</brief_title>
  <official_title>A Registry to Collect the Natural History of Solid Tumour Cancers in Patients Profiled With a Next-Generation Sequencing Test (WAYFIND-R)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      WAYFIND-R is a registry that aims to capture high-quality real-world data linking&#xD;
      next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a&#xD;
      solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform&#xD;
      to support the design and conduct of clinical and epidemiological research 2. To develop an&#xD;
      evidence-generation platform to better understand health outcomes and cancer care processes&#xD;
      3. To characterize the treatments and clinical course of solid tumor cancers in patients who&#xD;
      have undergone NGS testing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of registry entry until death, for up to 5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Solid Tumours</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male and Female adult participants who are diagnosed with solid tumour cancers (at any&#xD;
        anatomical location) and at any stage of the disease who have undergone an NGS test.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is an adult (according to the age of majority as defined by local&#xD;
             regulations)&#xD;
&#xD;
          -  Participant is currently diagnosed with any type of solid tumour cancer, at any stage&#xD;
             of the disease, at the enrollment date (informed consent date)&#xD;
&#xD;
          -  Participant has undergone NGS testing, no longer than 3 months prior to the enrollment&#xD;
             date, irrespective of the availability of test results&#xD;
&#xD;
          -  Informed consent has been obtained from the participant or legally authorized&#xD;
             representative, as per local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -Participant has a prior or current diagnosis of haematological malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID # MX39897 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Mayor MEDERI</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz; Departamento de Oncologia Medica</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Porto; Servico Pneumologia</name>
      <address>
        <city>Porto</city>
        <zip>4100-180</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HM Sanchinarro - CIOCC; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Colombia</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may be granted access to individual patient-level data through the data sharing environment of the Registry.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

